We see major unmet medical needs being fulfilled by our GI microbiome modulators in a variety of product formats compliant with a range of regulatory categories. The varied role of the microbiome, especially the hundreds of trillions of bacteria residing in our GI tract, is now an intense field of study. We see MBT as a leading company in leveraging this rapidly emerging science to develop innovative products for conditions with substantial unmet need.

Type 2 diabetes is among the most impactful indications of the 21st century, affecting millions of people and representing the largest single market for therapeutics. Definitive data show that diabetes and other metabolic diseases are linked to dysbiosis, an imbalance in the GI microbiome population. Advances in the science of the microbiome are now making it possible to develop new therapies based on modulation of the bacteria in the GI tract and their environment. As an early adopter of this approach, MBT is already well versed in leveraging the microbiome to design and develop innovative new therapies for the safe prevention and treatment of metabolic diseases. These therapies will span product formats and could potentially include medical foods, pharmaceuticals, supplements and foods (nutraceuticals). All our products will be supported by scientific evidence, including clinical trials when appropriate, and label claims will be evidence-based and in conformance with regulatory requirements and constraints.